Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Chief Legal Officer | September 05, 2025 | September 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date September 05, 2025 · Filed September 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 13,027 |
Reported balance
After 2025-09-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-05 · Purchase · Acquired 1,113 · Balance 13,027 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENDOCYTE INC
Report date December 21, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2018-12-21 · Disposition to issuer · Disposed 2,119 · Balance 0 F1: Includes 1,684 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018. F2: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2018-12-21 · Disposition to issuer · Disposed 23,750 · Balance 0 F3: This restricted stock unit ("RSU") award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 5, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2028-01-05 | Direct | 0 |
Reported balance
After 2018-12-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-21 · Disposition to issuer · Disposed 37,500 · Balance 0 F4: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 5, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,684 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018.
F2: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
F3: This restricted stock unit ("RSU") award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 5, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
F4: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 5, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Fresh Tracks Therapeutics, Inc.
Report date October 02, 2023 · Filed October 04, 2023
Section 16 reporting ended · disclosed 2023-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,419 |
Reported balance
After 2023-10-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-02 · Exercise / conversion · Acquired 20,000 · Balance 23,419 F1: The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer. F2: Each restricted stock unit converted into common stock on a one-for-one basis. F3: This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported. F4: On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split. |
| Common StockSEC Table I · non-derivative | Direct | 16,061 |
Reported balance
After 2023-10-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-10-02 · Tax withholding · Disposed 7,358 · Balance 16,061 F5: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-10-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-02 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each restricted stock unit converted into common stock on a one-for-one basis. F6: The restricted stock units vested in full on October 2, 2023. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 310 |
Reported balance
Holding disclosure · report date 2023-10-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 310 F4: On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer.
F2: Each restricted stock unit converted into common stock on a one-for-one basis.
F3: This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported.
F4: On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split.
F5: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.
F6: The restricted stock units vested in full on October 2, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2025 Filed Sep 9, 2025 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | PurchaseOrdinary Shares | 1,113 | $18.86 | $20,988.06 |
DisclosureSEC source: 0000950170-25-113800 · ownership.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,027 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,677 | $15.91 | $26,686.44 |
DisclosureSEC source: 0000950170-25-034670 · ownership.xml · nonDerivative · entry 3 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,914 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:22 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 56,603 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035533 · ownership.xml · derivative · entry 1 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,603 Underlying: Ordinary Shares · 56,603 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029. F2 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,741 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034670 · ownership.xml · derivative · entry 4 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,223 Underlying: Ordinary Shares · 16,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 16,741 vested on March 4, 2025, and 16,741 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 16,741 vested on March 4, 2025, and 16,741 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 3,150 | $15.73 | $49,563.99 |
DisclosureSEC source: 0000950170-25-034670 · ownership.xml · nonDerivative · entry 2 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,591 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:16 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034670 · ownership.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:46 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 66,964 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026140 · ownership.xml · derivative · entry 1 McAvoy David R. · CIK 0001758842 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,964 Underlying: Ordinary Shares · 66,964 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 16,741 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 16,741 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:40 UTC | Fresh Tracks Therapeutics, Inc. FRTX · Entity 90076 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-033914 · wk-form4_1696470013.xml · derivative · entry 4 McAvoy David R. · CIK 0001758842 · Gen Counsel, CCO, & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converted into common stock on a one-for-one basis. F6 · derivative.exercise_date: The restricted stock units vested in full on October 2, 2023. F6 · derivative.expiration_date: The restricted stock units vested in full on October 2, 2023. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:40 UTC | Fresh Tracks Therapeutics, Inc. FRTX · Entity 90076 | Tax withholdingCommon Stock | 7,358 | $0.98 | $7,209.37 |
DisclosureSEC source: 0001628280-23-033914 · wk-form4_1696470013.xml · nonDerivative · entry 2 McAvoy David R. · CIK 0001758842 · Gen Counsel, CCO, & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,061 F5 · shares: Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:40 UTC | Fresh Tracks Therapeutics, Inc. FRTX · Entity 90076 | Exercise / conversionCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-033914 · wk-form4_1696470013.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · Gen Counsel, CCO, & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer. F2 · price: Each restricted stock unit converted into common stock on a one-for-one basis. F3 · balance_after: This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported. F4 · balance_after: On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 18:49 UTC | Fresh Tracks Therapeutics, Inc. FRTX · Entity 90076 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000819050-23-000008 · wf-form4_167477696231987.xml · derivative · entry 1 McAvoy David R. · CIK 0001758842 · Gen Counsel, CCO, & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of issuer common stock upon settlement. F2 · derivative.exercise_date: The restricted stock units vest in full on the first anniversary of the grant date. F2 · derivative.expiration_date: The restricted stock units vest in full on the first anniversary of the grant date. Read SEC document |
| May 05, 2022 Filed May 9, 2022 16:17 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000819050-22-000049 · wf-form4_165212745351640.xml · derivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-05-05 F1 · derivative.exercise_date: The stock options will vest 25% on the first anniversary of the grant date, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| July 23, 2021 Filed Jul 27, 2021 16:42 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock | 18,124 | $0.67 | $12,137.64 |
DisclosureSEC source: 0000819050-21-000124 · wf-form4_162741845824709.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,879 Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 16:43 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000819050-21-000085 · wf-form4_162370341305839.xml · derivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The stock options will vest 25% on June 14, 2022, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| May 17, 2021 Filed May 19, 2021 17:02 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock | 7,980 | $0.80 | $6,384.00 |
DisclosureSEC source: 0001062993-21-004867 · form4.xml · nonDerivative · entry 2 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,980 Read SEC document |
| May 17, 2021 Filed May 19, 2021 17:02 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock | 18,622 | $0.80 | $14,897.60 |
DisclosureSEC source: 0001062993-21-004867 · form4.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,755 F1 · price: Represents the purchase of 18,622 shares in multiple transactions, ranging in price from $0.7942 to $0.8097 per share, resulting in a weighted average purchase price of $0.806. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:53 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-002790 · form4.xml · derivative · entry 4 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. F3 · derivative.exercise_date: These RSUs vested in full on March 16, 2021. F3 · derivative.expiration_date: These RSUs vested in full on March 16, 2021. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:53 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Tax withholdingCommon Stock | 8,750 | $1.14 | $9,975.00 |
DisclosureSEC source: 0001062993-21-002790 · form4.xml · nonDerivative · entry 2 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,133 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:53 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | Exercise / conversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-002790 · form4.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") converted into common stock on a one-for-one basis. Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 16:19 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock | 6,000 | $0.84 | $5,038.80 |
DisclosureSEC source: 0001062993-20-004584 · form4.xml · nonDerivative · entry 2 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 6,000 Read SEC document |
| September 18, 2020 Filed Sep 21, 2020 16:19 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock | 16,526 | $0.83 | $13,713.27 |
DisclosureSEC source: 0001062993-20-004584 · form4.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,883 F1 · price: Represents the purchase of 16,526 shares in multiple transactions, ranging in price from $0.8224 to $0.8429 per share, resulting in a weighted average purchase price of $0.8298. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 17:05 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001062993-20-004553 · form4.xml · derivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 19:52 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 30,435 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0000911916-20-000136 · edgar.xml · derivative · entry 2 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,435 Underlying: Common Stock · 30,435 shares Expires 2025-06-22 F1 · price: The reported securities were purchased by the reporting person at a combined public offering price of $1.15 per share of common stock and accompanying warrant exercisable for one share of common stock. Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 19:52 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | PurchaseCommon Stock | 30,435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000911916-20-000136 · edgar.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,357 F1 · price: The reported securities were purchased by the reporting person at a combined public offering price of $1.15 per share of common stock and accompanying warrant exercisable for one share of common stock. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 16:30 UTC | Fresh Tracks Therapeutics, Inc. BBI · Entity 90076 | GrantRestricted Stock Units · Derivative | 25,000 | $1.54 Strike: $1.54 | $38,500.00 |
DisclosureSEC source: 0001214659-20-002729 · marketforms-48377.xml · derivative · entry 4 McAvoy David R. · CIK 0001758842 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-03-15 Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerStock Option (right to buy) · Derivative | 37,500 | $21.04 Strike: $2.96 | $789,000.00 |
DisclosureSEC source: 0001104659-18-074358 · a4.xml · derivative · entry 3 McAvoy David R. · CIK 0001758842 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2028-01-05 F4 · price: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 5, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F4 · derivative.exercise_date: This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 5, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 23,750 | $24.00 | $570,000.00 |
DisclosureSEC source: 0001104659-18-074358 · a4.xml · nonDerivative · entry 2 McAvoy David R. · CIK 0001758842 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: This restricted stock unit ("RSU") award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 5, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document |
| December 21, 2018 Filed Dec 21, 2018 12:53 UTC | ENDOCYTE INC ECYT · Entity 161591 | Disposition to issuerCommon Stock | 2,119 | $24.00 | $50,856.00 |
DisclosureSEC source: 0001104659-18-074358 · a4.xml · nonDerivative · entry 1 McAvoy David R. · CIK 0001758842 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 1,684 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.